Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: VRTX stock price vs NWL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NWL's multiple
Needs NWL P/E.
Implied fair value · at VRTX's multiple
Needs Annual EPS is negative, VRTX P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
VERTEX PHARMACEUTICALS INC / MA · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
NEWELL BRANDS INC. · implied price per share
Bear
-$9.19
Base
-$9.00
Bull
-$8.67
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
VRTX vs AMGN
Gilead Sciences, Inc.
VRTX vs GILD
BIOGEN INC.
VRTX vs BIIB
Moderna, Inc.
VRTX vs MRNA
Illumina, Inc.
VRTX vs ILMN
PROCTER & GAMBLE Co
VRTX vs PG
COLGATE PALMOLIVE CO
VRTX vs CL
INTERNATIONAL BUSINESS MACHINES CORP
VRTX vs IBM
CLOROX CO /DE/
VRTX vs CLX
WHIRLPOOL CORP /DE/
VRTX vs WHR
ESTEE LAUDER COMPANIES INC
VRTX vs EL
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe VRTX can sustain its 8.9% revenue growth and 34.8% operating margin, then hold only with a strong conviction in continued premium execution because the current $482.40 price is far above both NWL-implied range and the DCF range.
VRTX trades at 10.2x P/S versus NWL at 0.4x, yet NWL-implied price is only $17.41-$163.81 versus VRTX's current $482.40. That creates an implied downside of -96.4%, indicating the market is valuing VRTX at a very large premium relative to NWL despite much stronger operating quality.
Supporting Metrics
